Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

6.645 +0.035 (+0.53%)
Streaming Delayed Price Updated: 1:09 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday ↗
One of the company's key drugs won't be challenged by a competing medication anytime soon. 
Via The Motley Fool
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript ↗
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Posts Record Q3 2025 Revenue but Misses Analyst Estimates ↗
Xeris Biopharma posts record Q3 2025 revenue of $74.4M, up 37% YoY, but misses earnings estimates. The company raises full-year guidance. 
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Xeris Biopharma Holdings ↗
 
Via Benzinga
News headline image
Earnings Outlook For Xeris Biopharma Holdings ↗
 
Via Benzinga
News headline image
Earnings Outlook For Xeris Biopharma Holdings ↗
 
Via Benzinga
News headline image
Xeris (XERS) Q2 Revenue Jumps 49% ↗
Via The Motley Fool
News headline image
Traders are paying attention to the gapping stocks in Thursday's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance ↗
Xeris Biopharma (XERS) Q2 2025 results beat estimates with $71.5M revenue (+48.8% YoY) and narrower losses. Stock surged 12.2% pre-market as Recorlev sales soared 136%. Raised full-year guidance to... 
Via Chartmill
Topics Earnings
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗
XERIS Biopharma (XERS) meets Minervini’s Trend Template with strong technicals and high growth momentum, including 47.9% quarterly revenue growth and a 93.95 Relative Strength score. 
Via Chartmill
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A High-Growth Stock Meeting Minervini’s Trend Template ↗
XERIS BIOPHARMA (XERS) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors. 
Via Chartmill
News headline image
Would Mark Minervini consider XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) a top stock pick? ↗
Why the high growth investor may take a look at XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS). A fundamental and technical analysis of (NASDAQ:XERS). 
Via Chartmill
News headline image
Xeris Biopharma - Possibly The Best Pharma Stock ↗
The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In ↗
The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected. 
Via Stocktwits
News headline image
These stocks are gapping in today's session ↗
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
Earnings Scheduled For March 6, 2025 ↗
 
Via Benzinga
News headline image
Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
More Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying ↗
 
Via Benzinga
News headline image
Xeris Biopharma And 2 Other Penny Stocks Insiders Are Buying ↗
 
Via Benzinga
News headline image
XERS Stock Earnings: Xeris Biopharma Holdings Beats EPS, Beats Revenue for Q2 2024 ↗
XERS stock results show that Xeris Biopharma Holdings beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Socket Mobile And 3 Other Stocks Under $3 Insiders Are Buying ↗
 
Via Benzinga
News headline image
XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024 ↗
XERS stock results show that Xeris Biopharma Holdings missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Why Are Xeris Biopharma Shares Moving Monday? ↗
Xeris Biopharma shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement with Beta Bionics. Xeris said it will work with Beta Bionics to develop and... 
Via Benzinga
News headline image
XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023 ↗
XERS stock results show that Xeris Biopharma Holdings met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Earnings Scheduled For March 6, 2024 ↗
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.